Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

Gerald Denys, Kim M. Koch, Michael J. Dowzicky

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Gram-positive isolates were collected from 76 medical centers within the 9 census regions across the United States. Methods: Antimicrobial susceptibilities were determined according to Clinical and Laboratory Standards Institute guidelines. Results: Vancomycin resistance among Enterococcus faecium isolates varied from 45.5% (New England) to 85.3% (East South Central). The lowest concentrations at which 90% of the isolates were inhibited (MIC90) were for tigecycline (0.06-0.12 μg/mL) and for linezolid (2-4 μg/mL). Methicillin-resistant Staphylococcus aureus (MRSA) varied from 27.4% (New England) to 62.4% (East South Central). All MRSA were susceptible to tigecycline, linezolid, and vancomycin. Penicillin-nonsusceptible Streptococcus pneumoniae ranged from 23.3% in the Pacific region to 54.5% in the East South Central region. Tigecycline, imipenem, levofloxacin, linezolid, and vancomycin all maintained MIC90 of ≤1 μg/mL against penicillin-nonsusceptible S pneumoniae in vitro, irrespective of region. Conclusion: This study demonstrates the variable rate of antimicrobial-resistant gram-positive organisms in the United States. Tigecycline may make a useful addition to the antimicrobial armamentarium.

Original languageEnglish (US)
Pages (from-to)521-526
Number of pages6
JournalAmerican Journal of Infection Control
Volume35
Issue number8
DOIs
StatePublished - Oct 1 2007

Fingerprint

Linezolid
Censuses
New England
Vancomycin
Methicillin-Resistant Staphylococcus aureus
Penicillins
Vancomycin Resistance
Enterococcus faecium
Levofloxacin
Imipenem
Streptococcus pneumoniae
Pneumonia
Guidelines
In Vitro Techniques
CL 331002
tigecycline

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

@article{5d56f3ed15124f4c9425222433645e41,
title = "Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial",
abstract = "Background: Gram-positive isolates were collected from 76 medical centers within the 9 census regions across the United States. Methods: Antimicrobial susceptibilities were determined according to Clinical and Laboratory Standards Institute guidelines. Results: Vancomycin resistance among Enterococcus faecium isolates varied from 45.5{\%} (New England) to 85.3{\%} (East South Central). The lowest concentrations at which 90{\%} of the isolates were inhibited (MIC90) were for tigecycline (0.06-0.12 μg/mL) and for linezolid (2-4 μg/mL). Methicillin-resistant Staphylococcus aureus (MRSA) varied from 27.4{\%} (New England) to 62.4{\%} (East South Central). All MRSA were susceptible to tigecycline, linezolid, and vancomycin. Penicillin-nonsusceptible Streptococcus pneumoniae ranged from 23.3{\%} in the Pacific region to 54.5{\%} in the East South Central region. Tigecycline, imipenem, levofloxacin, linezolid, and vancomycin all maintained MIC90 of ≤1 μg/mL against penicillin-nonsusceptible S pneumoniae in vitro, irrespective of region. Conclusion: This study demonstrates the variable rate of antimicrobial-resistant gram-positive organisms in the United States. Tigecycline may make a useful addition to the antimicrobial armamentarium.",
author = "Gerald Denys and Koch, {Kim M.} and Dowzicky, {Michael J.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.ajic.2006.11.004",
language = "English (US)",
volume = "35",
pages = "521--526",
journal = "American Journal of Infection Control",
issn = "0196-6553",
publisher = "Mosby Inc.",
number = "8",

}

TY - JOUR

T1 - Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

AU - Denys, Gerald

AU - Koch, Kim M.

AU - Dowzicky, Michael J.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Background: Gram-positive isolates were collected from 76 medical centers within the 9 census regions across the United States. Methods: Antimicrobial susceptibilities were determined according to Clinical and Laboratory Standards Institute guidelines. Results: Vancomycin resistance among Enterococcus faecium isolates varied from 45.5% (New England) to 85.3% (East South Central). The lowest concentrations at which 90% of the isolates were inhibited (MIC90) were for tigecycline (0.06-0.12 μg/mL) and for linezolid (2-4 μg/mL). Methicillin-resistant Staphylococcus aureus (MRSA) varied from 27.4% (New England) to 62.4% (East South Central). All MRSA were susceptible to tigecycline, linezolid, and vancomycin. Penicillin-nonsusceptible Streptococcus pneumoniae ranged from 23.3% in the Pacific region to 54.5% in the East South Central region. Tigecycline, imipenem, levofloxacin, linezolid, and vancomycin all maintained MIC90 of ≤1 μg/mL against penicillin-nonsusceptible S pneumoniae in vitro, irrespective of region. Conclusion: This study demonstrates the variable rate of antimicrobial-resistant gram-positive organisms in the United States. Tigecycline may make a useful addition to the antimicrobial armamentarium.

AB - Background: Gram-positive isolates were collected from 76 medical centers within the 9 census regions across the United States. Methods: Antimicrobial susceptibilities were determined according to Clinical and Laboratory Standards Institute guidelines. Results: Vancomycin resistance among Enterococcus faecium isolates varied from 45.5% (New England) to 85.3% (East South Central). The lowest concentrations at which 90% of the isolates were inhibited (MIC90) were for tigecycline (0.06-0.12 μg/mL) and for linezolid (2-4 μg/mL). Methicillin-resistant Staphylococcus aureus (MRSA) varied from 27.4% (New England) to 62.4% (East South Central). All MRSA were susceptible to tigecycline, linezolid, and vancomycin. Penicillin-nonsusceptible Streptococcus pneumoniae ranged from 23.3% in the Pacific region to 54.5% in the East South Central region. Tigecycline, imipenem, levofloxacin, linezolid, and vancomycin all maintained MIC90 of ≤1 μg/mL against penicillin-nonsusceptible S pneumoniae in vitro, irrespective of region. Conclusion: This study demonstrates the variable rate of antimicrobial-resistant gram-positive organisms in the United States. Tigecycline may make a useful addition to the antimicrobial armamentarium.

UR - http://www.scopus.com/inward/record.url?scp=34948908732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948908732&partnerID=8YFLogxK

U2 - 10.1016/j.ajic.2006.11.004

DO - 10.1016/j.ajic.2006.11.004

M3 - Article

C2 - 17936143

AN - SCOPUS:34948908732

VL - 35

SP - 521

EP - 526

JO - American Journal of Infection Control

JF - American Journal of Infection Control

SN - 0196-6553

IS - 8

ER -